Global Leading Market Research Publisher QYResearch announces the release of its latest report *"Lentinan Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032"*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Lentinan Drugs market, including market size, share, demand, industry development status, and forecasts for the next few years. For oncologists, immunologists, and supportive care specialists, cancer patients undergoing chemotherapy or radiation therapy frequently experience immunosuppression – increased risk of infections (neutropenic fever, pneumonia, sepsis), delayed recovery, and reduced quality of life. Colony-stimulating factors (G-CSF) stimulate neutrophil production but have significant side effects (bone pain, splenic rupture). Lentinan drugs offer an alternative immunoadjuvant approach – a purified beta-1,3/1,6-glucan polysaccharide derived from Lentinula edodes (shiitake mushroom), intravenous or oral, that activates innate immune cells (macrophages, dendritic cells, natural killer cells) via dectin-1 and complement receptor 3, restoring immune function without stimulating tumor growth. Approved in Japan (1985), China (1990s), and other Asian countries as adjunctive therapy for gastric, colorectal, lung, and other cancers – improving survival, reducing chemotherapy side effects, and enhancing quality of life. The global market for Lentinan Drugs was estimated to be worth USmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/reports/5975079/lentinan-drugs Understanding Lentinan Drugs: Mechanism and Clinical Application Lentinan is a high molecular weight (300-500 kDa) beta-1,3/1,6-glucan with triple-helix conformation. Purified from the mycelium of shiitake mushrooms via hot water extraction, ethanol precipitation, chromatography. Mechanism of action: Immune receptor binding: Dectin-1 (C-type lectin receptor) on macrophages, dendritic cells, neutrophils, and complement receptor 3 (CR3) – triggers intracellular signaling (Syk, NF-κB), promoting cytokine secretion (IL-1β, IL-6, TNF-α, GM-CSF, IFN-γ). Macrophage activation: Enhanced phagocytosis, antigen presentation, production of reactive oxygen/nitrogen species (anti-tumor effects). Natural killer (NK) cell activation: Increased cytotoxic activity (killing tumor cells). T cell modulation: Enhanced Th1 response, increased cytotoxic T lymphocyte (CTL) activity. Clinical applications (approved indications): Japan: Adjuvant therapy for gastric cancer (post-surgery, in combination with chemotherapeutic agents – tegafur, mitomycin C, 5-FU). Increases survival (4-year survival 81% vs. 64% control, meta-analysis, Japanese studies). China: Gastric, colorectal, lung, esophageal, breast, nasopharyngeal cancers – intravenous lentinan (1-2 mg/week) during chemotherapy or radiotherapy. Improves immune function (CD4+/CD8+ ratio, NK cell activity), reduces leukopenia, reduces infectious complications, improves quality of life (QoL) scores, prolongs survival. China National Medical Products Administration (NMPA) approved. Other: Unconfirmed use in hepatitis, HIV (immunomodulation). No formal approvals. Meta-analysis evidence (10 RCTs, N=1,500 patients, gastric cancer): Lentinan + chemotherapy vs. chemotherapy alone – overall survival hazard ratio 0.65 (95% CI 0.52-0.81), progression-free survival improved, leukopenia reduced 30-40%. Adverse effects: Well-tolerated. Mild nausea (5%), slight fever (3-5%), and injection site reaction (2%). No major organ toxicity. Contraindication: hypersensitivity to shiitake (rare). Market Segmentation by Formulation Injectable Drugs (Dominant, ~70-75% of market value): Lyophilized powder (vial) for reconstitution (sterile water, saline, or 5% dextrose). Intravenous infusion (over 30-60 minutes) – 1-2 mg weekly, typically 4-8 weeks per course, repeated cycles. Hospital administered. Injectable formulation higher potency (systemic bioavailability), used in oncology inpatient/outpatient infusion suites. Approved indications (gastric, colorectal, lung, esophageal). Require medical supervision (anaphylaxis rare but monitoring). Market share larger because: Clinical evidence stronger (RCTs, meta-analyses). Reimbursement coverage (Japan NHI, China National Reimbursement Drug List, some provinces). Hospital preferred administration. Oral Drugs (Smaller, ~25-30% of market value): Capsules or tablets (lentinan extract, lower purity, lower dose). Bioavailability <20% (due to high molecular weight, poor absorption). Used for maintenance therapy (post-chemotherapy recovery), general immune support (elderly, recurrent infections). Marketed in China as dietary supplements (not registered as drug in many countries). Lower regulatory bar, easier to access OTC. Clinical evidence limited (small studies, open label). Price lower than injectable. Growing segment (patient preference for oral, home administration, convenience). However, efficacy debated (no high-quality RCTs). Physicians may prescribe off-label injectable only. Market Segmentation by Application Hospital (Largest, ~70-75% of market value): Lentinan injectable use – oncology departments (medical oncology, radiation oncology), immunology, gastroenterology (gastric cancer). Administered in hospital day unit or inpatient. Prescribed by oncologists (familiar with Japanese/Chinese guidelines). Reimbursement coverage (China NRDL, Japan NHI). Hospital share high due to IV administration requirement. Some pharmacies associated with hospitals dispense oral lentinan. Pharmacy (Retail, Fastest-Growing): Oral lentinan capsules/tablets sold in retail pharmacies (OTC or prescription depending on country). China – licensed pharmacies (prescription required if drug; as supplement freely sold). Used by patients post-chemotherapy (maintenance), family members seeking immune support (elderly, frequent colds). Pharmacy segment growing (direct-to-consumer marketing, e-commerce platforms – JD Health, Alibaba Health, Tmall Pharmacy). However, regulatory gray area – lentinan not approved as drug outside Asia, sold as supplement. Consumers may self-treat without physician guidance. Others (Elderly care, wellness clinics, direct-to-consumer): Nursing homes – lentinan for elderly (immune boosting). Wellness clinics (integrative oncology, functional medicine) – lentinan capsules, IV infusion (if injectable). Wellness tourism. Small share. Competitive Landscape and Exclusive Market Observation (2025–2026) Key Players: Jiangsu Kanion Pharmaceutical (Chinese, major manufacturer injectable lentinan, approved by NMPA, large production scale, includes gastric, colorectal, lung labels, market leader in China), Jinling Pharmaceutical (China, lentinan injection – lyophilized powder, hospital sales), Zhendong Pharmaceutical (China, oral capsules, lentinan extract – OTC, also lentinan injection), Luye Pharma (China, injectable, oncology focus), Nanjing Easeheal Pharmaceutical (China, injectable lyophilized). Exclusive Industry Insight (H1 2026): Lentinan drugs market is China-dominated and Asia-centric, with minimal Western presence: Geographic scope: Registered drugs only in China, Japan (Ajinomoto lentinan – abandoned? no longer marketed). Taiwan, South Korea (minor). Not approved in US, Europe, Canada. Western oncologists largely unaware. International use (US, EU) limited to integrative medicine, supplement market (lentinan capsules from mushroom extracts, not drug-grade, no quality standardization). Clinical evidence acceptance: Japanese gastric cancer guidelines (2018, 2021) list lentinan as optional adjuvant (Grade C recommendation, evidence moderate). Chinese guidelines (CSCO, 2024) supportive. Western NCCN guidelines – no recommendation (insufficient evidence, not approved, not available). Therefore, market isolated. Generic competition: Lentinan off-patent (discovered 1960s, Japanese patent expired). Multiple Chinese manufacturers (Kanion, Jinling, Zhendong, Luye, Easeheal). Pricing competition within China VBP? Not yet included in national VBP, but provincial procurement. Price stable (injectable ¥500-1,000 per vial, oral ¥30-100 per pack). Margins moderate. Regulatory environment: China NMPA requires lentinan finished product testing (purity, potency, bacterial endotoxins, sterility). Batch release. Indonesian, Vietnamese, Thai regulators accept. Growth drivers: Rising cancer incidence – China 4.8 million new cases annually (2022), gastric, colorectal, lung, breast high. Chemotherapy-induced immunosuppression common (60-80% patients). Lentinan supportive care hospital. Also, COVID-19 immune support promoted? No evidence. User case: Jiangsu Kanion Pharmaceutical – largest lentinan product "Lentinan for Injection" (lyophilized, 1 mg/vial), sold in 1,000+ Chinese hospitals. Label: "adjuvant for gastric, colorectal, lung cancer combined with chemo/radiotherapy". Kanion clinical trial (N=360 gastric cancer patients) – 5-year survival 62% vs 48% control. Reimbursement by China National Reimbursement Drug List (category B, patient copay 20-30%). Volume 2-3 million vials/year? revenue estimate. User case 2: Zhendong Pharmaceutical – "Lentinan Capsules" (20 mg, 30 capsules pack) OTC. Marketing: "immune regulator, helpful for frequent illness, fatigue". Sold in local pharmacies, Tmall, JD Health. 100,000+ packages monthly? Not oncology focused. Oral market volume high, lower price. Technical Deep Dive: Beta-Glucan Standardization and Quality Lentinan drugs require rigorous quality control: molecular weight distribution (300-500 kDa), polysaccharide purity (>80%), beta-1,3/1,6 linkage ratio, low endotoxin (<0.5 EU/mg for injection), no protein contamination. Chinese manufacturers vs. mushroom extract supplements: supplements may contain mixtures of beta-glucans from different sources (yeast, oats, other mushrooms), not standardized. Clinical trials used specific lentinan (Ajinomoto, Kanion). Inconsistent potency leads to variable efficacy. Future Outlook (2026–2032): Drivers and Challenges Growth Drivers: Rising Asian cancer burden: China, India, Indonesia, Japan, South Korea gastrointestinal cancers (stomach, colorectal) high incidence. Need for supportive care (immunocompetence during chemo). Lentinan established, reimbursed. Integrative oncology growth globally: Western cancer centers adopting complementary therapies (acupuncture, nutrition, mind-body). Lentinan research may expand if RCTs published. Potential international registration (more evidence needed). Oral segment expansion: Elderly prefer oral supplements, less clinic visits. E-commerce growth in China health products. Constraints: Limited Western acceptance: No FDA or EMA approval. Western oncologists skeptical (lack of large trial, not head-to-head with G-CSF). Publication bias (mostly Chinese/Japanese). Generic price pressure: VBP inclusion likely (injectable) within 2-3 years, price erosion 70-80%. Revenue drop. Competition from other immunomodulators: Bacterial extracts (OK-432, Picibanil), fungal extracts (schizophyllan, SPG), cytokines (IL-2, GM-CSF), checkpoint inhibitors (pembrolizumab, nivolumab – expensive, different MOA). Lentinan niche. Emerging research: Lentinan + immune checkpoint inhibitors (PD-1/PD-L1 blockers) in preclinical models – synergistic effect (macrophage polarization, enhanced T cell infiltration). Clinical trials (China). Could reposition lentinan as immuno-oncology combination? Not yet. The market projected moderate growth (CAGR 5-7% volume, 3-5% value) in Asia. Injectable dominant, oral faster-growing (lower price barrier). China largest (>70% market). International expansion limited until Western approvals. Contact Us If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp